Metastatic Prostate Adenocarcinoma Clinical Trials

12 recruiting

Metastatic Prostate Adenocarcinoma Trials at a Glance

14 actively recruiting trials for metastatic prostate adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Seattle, Chicago, and Houston. Lead sponsors running metastatic prostate adenocarcinoma studies include Fred Hutchinson Cancer Center, City of Hope Medical Center, and Alliance for Clinical Trials in Oncology.

Browse metastatic prostate adenocarcinoma trials by phase

Treatments under study

About Metastatic Prostate Adenocarcinoma Clinical Trials

Looking for clinical trials for Metastatic Prostate Adenocarcinoma? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Prostate Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Prostate Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8Metastatic Prostate Small Cell Neuroendocrine CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation+1 more
National Cancer Institute (NCI)30 enrolled13 locationsNCT05691465
Recruiting
Phase 1Phase 2

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8+2 more
Vadim S Koshkin30 enrolled1 locationNCT05113537
Recruiting
Phase 1Phase 2

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
University of Michigan Rogel Cancer Center39 enrolled3 locationsNCT06616155
Recruiting
Phase 3

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Stage IVB Prostate Cancer AJCC v8Metastatic Prostate AdenocarcinomaCastration-Sensitive Prostate Carcinoma
Alliance for Clinical Trials in Oncology1,260 enrolled177 locationsNCT06931340
Recruiting
Phase 1Phase 2

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
Fred Hutchinson Cancer Center48 enrolled1 locationNCT06236139
Recruiting
Phase 2

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Prostate AdenocarcinomaProstate AdenocarcinomaCastration-resistant
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins47 enrolled2 locationsNCT04704505
Recruiting
Phase 2

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Stage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma+2 more
City of Hope Medical Center70 enrolled1 locationNCT04734730
Recruiting
Phase 2

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
Fred Hutchinson Cancer Center15 enrolled1 locationNCT06145633
Recruiting
Phase 2

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
University of Washington69 enrolled1 locationNCT06039371
Recruiting
Phase 2

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

Recurrent Prostate AdenocarcinomaOligometastatic Prostate Adenocarcinoma
Jonsson Comprehensive Cancer Center107 enrolled1 locationNCT07150715
Recruiting
Phase 3

Measuring Oncological Value of Exercise and Statin

Breast CancerMetastatic Breast CancerOvarian Cancer+9 more
Tampere University Hospital240 enrolled1 locationNCT05796973
Recruiting
Phase 2

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8+2 more
University of Utah33 enrolled1 locationNCT05168618
Recruiting

Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer

Metastatic Prostate AdenocarcinomaPSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio University Hospital150 enrolled1 locationNCT06850545
Recruiting
Phase 2

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

Stage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma+2 more
M.D. Anderson Cancer Center200 enrolled1 locationNCT05054296